FDA Plays

[colorofmoney]

Speculators Betting on BioElectronics' Upcoming Study Results

* Press Release
* Source: BioMedReports.Com
* On 11:46 am EST, Wednesday November 11, 2009
Companies:
Bioelectronics Corporation

LOS ANGELES, CA--(Marketwire - 11/11/09) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, reports that investors are betting that BioElectronics' (Pinksheets:BIEL - News) upcoming medical study results will be significant.

The fact that a U.S. Food and Drug Administration advisory panel and federal regulators have taken aim at over-the-counter (OTC) acetaminophen products is not just the stuff of recent headlines. In fact, since as far back as 1977, FDA advisers have recommended explicit warnings not to exceed the dose or take acetaminophen for more than 10 days "because severe liver damage may occur." Back then, the FDA never followed that advice although they pledged to quickly consider its advisers' recommendations.

The pendulum has finally swung and now the agency is going out of its way to educate the public after official studies found that many people consume more than the recommended dose of these pain relievers in the mistaken belief that taking more will prove more effective against pain without posing health risks.

That push and the results of a soon to be released study by BioElectronics Corp. (Pinksheets:BIEL - News) set the table for an intriguing penny play in the coming days. With investors riding the wave of excitement about BIEL's technology and pending FDA decisions, the upcoming news flash will likely make shares of the micro-cap company run up again.

Company officials won't yet officially disclose what the study results will reveal, but there are strong hints in what was released as part of the pilot section of the study last month. That Institutional Review Board (IRB) supervised study is directed at comparing the effects of the company's ActiPatch� Therapy to acetaminophen in the form of Extra Strength Tylenol� for the treatment of delayed onset muscle soreness (DOMS).

The complete report is available now at BioMedReports.Com:

http://biomedreports.com/articles/most-popular/17424-banking-on-biels-upcoming-study-results-against-tylenol.html

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

About BioMedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to http://BioMedReports.com
Contact:



Media Contact:
M. Davila
Assistant Editor
BioMedReports.Com
e-mail: Email Contact
Tel: [phone]
Fax: [phone]